Browse 90 Durlaza Medical Studies Across 265 Cities
18 Phase 3 Trial · 768 Durlaza Clinics
What Are Durlaza Clinical Trials?
Durlaza (Aspirin Capsules) clinical trials are research studies that test if Durlaza is safe and effective in people. Aspirin is a drug that is being studied for the treatment of heart disease and stroke. However, standard treatments of this drug include relief of symptoms from pain, fever, acute coronary syndrome, ischemic stroke, and transient ischemic attacks.
Why Is Durlaza Being Studied in Clinical Trials?
Durlaza is being studied in clinical trials because researchers are testing its effectiveness in cardiovascular diseases. There are also studies testing to see if Aspirin is better than anticoagulation in cervical artery dissection.
Aside from treatment, studies are also being conducted to see if there are any adverse effects of taking populations off of Durlaza without any clinical indication.
There is extensive use of Aspirin tablets. Thus, there are many different types of applications that Durlaza can be used. However, the main clinical testing is for blood clotting and heart-related issues.
How Does Durlaza Work?
The mechanism of action for Durlaza is still being studied. However, some scientists believe Durlaza works by inhibiting the cyclooxygenase (COX) enzyme. This enzyme is responsible for the production of prostaglandins and thromboxanes. Prostaglandins are known to promote inflammation, while thromboxanes are known to promote clotting. Therefore, by inhibiting the COX enzyme, Durlaza theoretically reduces both inflammation and clotting.
Before Durlaza, common treatments were either anti-inflammatory drugs or anticoagulants. Durlaza is unique because it is a single drug that inhibits both processes. This makes Durlaza a very promising treatment option for heart disease and stroke.
What Are Some of The Breakthrough Clinical Trials Involving Durlaza?
Here are some of the breakthrough Clinical Trials involving Aspirin:
2013: This early 2013 study shows that patients with Transient Ischemic Attacks (TIA) or Minor Ischemic Stroke showed more effectiveness to Aspirin and Clopidogrel than with Aspirin use alone. Additionally, they found that using Aspirin did not increase the risk of hemorrhage, which is essential to note.
2020: This study tests to see if Durlaza paired with Ticagrelor or Aspirin alone can improve outcomes in patients with an ischemic stroke. Results found that Ticagrelor-Aspirin for stroke or death was lower in this group. However, the Ticagrelor group had more severe bleeding.
2021: A polypill that includes statins, blood-pressure-lowering drugs, and Aspirin was tested to see if it can reduce the risk of cardiovascular disease. The findings found that the polypill effectively lowered the incidence of cardiovascular events in patients at intermediate cardiovascular risks versus a placebo polypill.
Who Are The Key Opinion Leaders On Durlaza Clinical Trial Research?
Dr. Peter M. Rothwell is a Professor of Neurological Sciences and Consultant Neurologist at the University of Oxford in the United Kingdom. He is also the Lead for Prevention of Stroke at the Oxford University Hospitals NHS Foundation Trust.
Dr. John A. Eikelboom is a Staff Cardiologist and Senior Investigator at the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada.
Dr. Nancy R. Cook is a Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts.